{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:00:11Z","timestamp":1794034811188,"version":"4.8.0"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"DOI":"10.13039\/501100007446","name":"Deanship of Scientific Research at King Khalid University","doi-asserted-by":"publisher","award":["RGP-1\/351\/1443"],"award-info":[{"award-number":["RGP-1\/351\/1443"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The severe respiratory infections in the current pandemic coronavirus disease-19\n(COVID-19) have influenced more or less every human life. The first person to get infected with\nthis virus was reported in the capital of Hubei province (Wuhan), China, in late December 2019.\nSince the disease has been declared a pandemic, research scholars and experts have been manufacturing\nnew vaccines or targeted therapies to curb the spread of SARS-CoV-2. However, only limited\noptions have emerged so far, which yet require complete scientific validation by long-term data\ncollection regarding safety and efficacy. In the wake of the recent emerging wave of the pandemic\nviz omicron variant, changing facets of the viral genome and dearth of preventative and therapeutic\npossibilities for the management of COVID-19, the usage of Convalescent Plasma Therapy (CPT)\nmay be looked at as a potentially viable option of treatment in the existing situation. Earlier, immune\nplasma has been used with success in the management of H1N1 influenza virus, MERS-CoV,\nand SARS-CoV-1 epidemics. In the present unpredictable situation created by the COVID-19 pandemic,\nthe CPT is used with a positive outcome amongst many infected individuals in different\nparts of the world with acceptable efficacy. This article aimed to present an up-to-date evaluation of\nexisting literature on the efficacy of convalescent plasma as a potential therapy, its safety and effectiveness\nand the challenges in treating COVID-19.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666230202144314","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T03:55:16Z","timestamp":1675396516000},"page":"1515-1523","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Convalescent Plasma Therapy against COVID-19: An Update on the\nChanging Facets of the ongoing Pandemic"],"prefix":"10.2174","volume":"24","author":[{"given":"Saquib Shahabe","family":"Abullais","sequence":"additional","affiliation":[{"name":"Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Restorative Dental Sciences, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadma","family":"Wahab","sequence":"additional","affiliation":[{"name":"Department of\nPharmacognosy, College of Pharmacy, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Periodontology, Dr. H. S. J.\nInstitute of Dental Sciences, Punjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Yahya","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences,\nCollege of Applied Medical Sciences, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik Mohamed","family":"Shamsudeen","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Science and Oral\nBiology, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik","family":"Mohammed  Asif","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Science and Oral\nBiology, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amel Ibrahim","family":"Faragalla","sequence":"additional","affiliation":[{"name":"Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Fadul","family":"Elagib","sequence":"additional","affiliation":[{"name":"Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, Abha, KSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"COVID-19 Map - Johns hopkins coronavirus resource center. Available from:  [Accessed on January 16, 2022]."},{"key":"ref=2","unstructured":"COVID-19 coronavirus pandemic. Available from:  [accessed on March 6, 2022]"},{"key":"ref=3","year":"2021","unstructured":"International Monetary Fund (IMF). World Economic Outlook, October 2021: After-Effects of the COVID-19 Pandemic: Prospects for Medium-Term Economic Damage. International Monetary Fund: Washington, DC, Available from: 2021"},{"key":"ref=4","year":"2021","unstructured":"Tackling the mental health impact of the COVID-19 crisis: An integrated, whole-of-society response. OECD Available from: 2021","journal-title":"OECD"},{"key":"ref=5","year":"2022","unstructured":"Saudi MoH protocol for patients suspected of confirmed with COVID-19. Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection. Available from: 2022"},{"key":"ref=6","year":"2022","unstructured":"Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Available from: 2022"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa2033700","volume":"384","author":"Libster R.","year":"2021","unstructured":"Libster R.; P&#xE9;rez Marc G.; Wappner D.; Coviello S.; Bianchi A.; Braem V.; Esteban I.; Caballero M.T.; Wood C.; Berrueta M.; Rondan A.; Lescano G.; Cruz P.; Ritou Y.; Fern&#xE1;ndez Vi&#xF1;a V.; &#xC1;lvarez Paggi D.; Esperante S.; Ferreti A.; Ofman G.; Ciganda &#xC1;.; Rodriguez R.; Lantos J.; Valentini R.; Itcovici N.; Hintze A.; Oyarvide M.L.; Etchegaray C.; Neira A.; Name I.; Alfonso J.; L&#xF3;pez Castelo R.; Caruso G.; Rapelius S.; Alvez F.; Etchenique F.; Dimase F.; Alvarez D.; Aranda S.S.; S&#xE1;nchez Yanotti C.; De Luca J.; Jares Baglivo S.; Laudanno S.; Nowogrodzki F.; Larrea R.; Silveyra M.; Leberzstein G.; Debonis A.; Molinos J.; Gonz&#xE1;lez M.; Perez E.; Kreplak N.; Pastor Arg&#xFC;ello S.; Gibbons L.; Althabe F.; Bergel E.; Polack F.P.; Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021,384(7),610-618","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"100931","DOI":"10.1016\/j.eclinm.2021.100931","volume":"36","author":"Rejeki M.S.","year":"2021","unstructured":"Rejeki M.S.; Sarnadi N.; Wihastuti R.; Fazharyasti V.; Samin W.Y.; Yudhaputri F.A.; Johar E.; Nurainy N.; Bachtiar N.S.; Muljono D.H.; Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries. E Clin Med 2021,36,100931","journal-title":"E Clin Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinmicnews.2021.02.001","volume":"43","author":"Ripoll J.G.","year":"2021","unstructured":"Ripoll J.G.; van Helmond N.; Senefeld J.W.; Wiggins C.C.; Klassen S.A.; Baker S.E.; Larson K.F.; Murphy B.M.; Andersen K.J.; Ford S.K.; Casadevall A.; Joyner M.J.; Convalescent plasma for infectious diseases: Historical framework and use in COVID-19. Clin Microbiol Newsl 2021,43(4),23-32","journal-title":"Clin Microbiol Newsl"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"Mair-Jenkins J.","year":"2015","unstructured":"Mair-Jenkins J.; Saavedra-Campos M.; Baillie J.K.; Cleary P.; Khaw F.M.; Lim W.S.; Makki S.; Rooney K.D.; Nguyen-Van-Tam J.S.; Beck C.R.; The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis 2015,211(1),80-90","journal-title":"J Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"m3939","DOI":"10.1136\/bmj.m3939","volume":"371","author":"Agarwal A.","year":"2020","unstructured":"Agarwal A.; Mukherjee A.; Kumar G.; Chatterjee P.; Bhatnagar T.; Malhotra P.; PLACID trial collaborators convalescent plasma in the management of moderate COVID-19 in adults in india: Open label phase ii multicenter randomised controlled trial (PLACID Trial). BMJ 2020,371,m3939","journal-title":"BMJ"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJMoa2031304","volume":"384","author":"Simonovich V.A.","year":"2021","unstructured":"Simonovich V.A.; Burgos Pratx L.D.; Scibona P.; Beruto M.V.; Vallone M.G.; V&#xE1;zquez C.; Savoy N.; Giunta D.H.; P&#xE9;rez L.G.; S&#xE1;nchez M.L.; Gamarnik A.V.; Ojeda D.S.; Santoro D.M.; Camino P.J.; Antelo S.; Rainero K.; Vidiella G.P.; Miyazaki E.A.; Cornistein W.; Trabadelo O.A.; Ross F.M.; Spotti M.; Funtowicz G.; Scordo W.E.; Losso M.H.; Ferniot I.; Pardo P.E.; Rodriguez E.; Rucci P.; Pasquali J.; Fuentes N.A.; Esperatti M.; Speroni G.A.; Nannini E.C.; Matteaccio A.; Michelangelo H.G.; Follmann D.; Lane H.C.; Belloso W.H.; PlasmAr study group. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N Engl J Med 2021,384(7),619-629","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/life11040354","volume":"11","author":"Franchini M.","year":"2021","unstructured":"Franchini M.; Liumbruno GM.; Piacentini G.; Glingani C.; Zaffanello M.; The three pillars of COVID-19 convalescent plasma therapy. Life 2021,11(4),354","journal-title":"Life"},{"key":"ref=14","unstructured":"Coronavirus (COVID-19) vaccinations 2022. Available from:  [Accessed on March 11, 2022"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/microorganisms10020451","volume":"10","author":"Arora S.","year":"2022","unstructured":"Arora S.; Grover V.; Saluja P.; Algarni Y.A.; Saquib S.A.; Asif S.M.; Batra K.; Alshahrani M.Y.; Das G.; Jain R.; Ohri A.; Literature review of omicron: A grim reality amidst covid-19. Microorganisms 2022,10(2),451","journal-title":"Microorganisms"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"Liu L.","year":"2021","unstructured":"Liu L.; Iketani S.; Guo Y.; Chan J.F-W.; Wang M.; Liu L.; Luo Y.; Chu H.; Huang Y.; Nair M.S.; Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature 2021,602(7898),676-681","journal-title":"Nature"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"106716","DOI":"10.1016\/j.rmed.2021.106716","volume":"191","author":"Mohiuddin M.","year":"2022","unstructured":"Mohiuddin M.; Kasahara K.; Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options. Respir Med 2022,191,106716","journal-title":"Respir Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.xphs.2022.06.004","volume":"111","author":"Sahin G.","year":"2022","unstructured":"Sahin G.; Akbal-Dagistan O.; Culha M.; Erturk A.; Basarir N.S.; Sancar S.; Yildiz-Pekoz A.; Antivirals and the potential benefits of orally inhaled drug administration in COVID-19 treatment. J Pharm Sci 2022,111(10),2652-2661","journal-title":"J Pharm Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2174\/18755704MTEwhNDgg4","volume":"18","author":"Wahab S.","year":"2021","unstructured":"Wahab S.; Ahmad I.; Usmani S.; Ahmad M.P.; Efficacy of dexamethasone for the treatment of COVID-19 infection: A perspective review. Curr Drug Deliv 2021,18(5),546-554","journal-title":"Curr Drug Deliv"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"113499","DOI":"10.1016\/j.biopha.2022.113499","volume":"153","author":"Mohamed Y.","year":"2022","unstructured":"Mohamed Y.; El-Maradny Y.A.; Saleh A.K.; Nayl A.A.; El-Gendi H.; El-Fakharany E.M.; A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment. Biomed Pharmacother 2022,153,113499","journal-title":"Biomed Pharmacother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.joim.2022.06.006","volume":"20","author":"Wu H.","year":"2022","unstructured":"Wu H.; Ji C.; Dai R.; Hei P.; Liang J.; Wu X.; Li Q.; Yang J.; Mao W.; Guo Q.; Traditional chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses. J Integr Med 2022,20(5),416-426","journal-title":"J Integr Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2174\/18734286MTEykOTUaz","volume":"27","author":"Wahab S.","year":"2021","unstructured":"Wahab S.; Ahmad I.; Irfan S.; Baig M.H.; Farouk A-E.; Dong J-J.; Use of natural compounds as a potential therapeutic agent against COVID-19. Curr Pharm Des 2021,27(9),1144-1152","journal-title":"Curr Pharm Des"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1515\/dx-2020-0161","volume":"8","author":"Franchini M.","year":"2021","unstructured":"Franchini M.; Glingani C.; Liumbruno G.M.; Potential mechanisms of action of convalescent plasma in COVID-19. Diagnosis 2021,8(4),413-420","journal-title":"Diagnosis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/vox.13091","volume":"116","author":"Focosi D.","year":"2021","unstructured":"Focosi D.; Franchini M.; COVID-19 convalescent plasma therapy: Hit fast, hit hard! Vox Sang 2021,116(9),935-942","journal-title":"Vox Sang"},{"key":"ref=25","year":"2022","unstructured":"Mayo clinic convalescent plasma therapy Available from:[accessed on Feb 24, 20222022"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"Casadevall A.","year":"2020","unstructured":"Casadevall A.; Pirofski L.; The convalescent sera option for containing COVID-19. J Clin Invest 2020,130(4),1545-1548","journal-title":"J Clin Invest"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1001\/jama.1937.02780090001001","volume":"108","author":"Cecil R.L.","year":"1937","unstructured":"Cecil R.L.; Effects of very early serum treatment in pneumococcus type I pneumonia. J Am Med Assoc 1937,108(9),689-692","journal-title":"J Am Med Assoc"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1084\/jem.17.5.553","volume":"17","author":"Flexner S.","year":"1913","unstructured":"Flexner S.; The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J Exp Med 1913,17(5),553-576","journal-title":"J Exp Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/vox.12926","volume":"115","author":"Tiberghien P.","year":"2020","unstructured":"Tiberghien P.; Lamballerie X.; Morel P.; Gallian P.; Lacombe K.; Yazdanpanah Y.; Collecting and evaluating convalescent plasma for COVID-19 treatment: Why and how? Vox Sang 2020,115(6),488-494","journal-title":"Vox Sang"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/vox.12939","volume":"115","author":"Epstein J.","year":"2020","unstructured":"Epstein J.; Burnouf T.; Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang 2020,115(6),485-487","journal-title":"Vox Sang"},{"key":"ref=31","year":"2020","unstructured":"Advancing transfusion and cellular therapies worldwide aabb), COVID-19 convalescent plasma collection: Donor eligibility, processing, labeling, and distribution. Available from: 2020"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e00117","DOI":"10.1128\/mBio.00117-17","volume":"8","author":"Kaufmann S.H.E.","year":"2017","unstructured":"Kaufmann S.H.E.; Remembering emil von behring: from tetanus treatment to antibody cooperation with phagocytes. MBio 2017,8(1),e00117-e17","journal-title":"MBio"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/vox.12927","volume":"115","author":"Wong H.K.","year":"2020","unstructured":"Wong H.K.; Lee C.K.; Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 2020,115(7),545-547","journal-title":"Vox Sang"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1097\/CCM.0b013e3181d44c1e","volume":"38","author":"Luke T.C.","year":"2010","unstructured":"Luke T.C.; Casadevall A.; Watowich S.J.; Hoffman S.L.; Beigel J.H.; Burgess T.H.; Hark back: Passive immunotherapy for influenza and other serious infections. Crit Care Med 2010,38(4),e66-e73","journal-title":"Crit Care Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1172\/JCI138745","volume":"130","author":"Bloch E.M.","year":"2020","unstructured":"Bloch E.M.; Shoham S.; Casadevall A.; Sachais B.S.; Shaz B.; Winters J.L.; van Buskirk C.; Grossman B.J.; Joyner M.; Henderson J.P.; Pekosz A.; Lau B.; Wesolowski A.; Katz L.; Shan H.; Auwaerter P.G.; Thomas D.; Sullivan D.J.; Paneth N.; Gehrie E.; Spitalnik S.; Hod E.A.; Pollack L.; Nicholson W.T.; Pirofski L.; Bailey J.A.; Tobian A.A.R.; Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020,130(6),2757-2765","journal-title":"J Clin Invest"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"Hung I.F.N.","year":"2011","unstructured":"Hung I.F.N.; To K.K.W.; Lee C.K.; Lee K.L.; Chan K.; Yan W.W.; Liu R.; Watt C.L.; Chan W.M.; Lai K.Y.; Koo C.K.; Buckley T.; Chow F.L.; Wong K.K.; Chan H.S.; Ching C.K.; Tang B.S.F.; Lau C.C.Y.; Li I.W.S.; Liu S.H.; Chan K.H.; Lin C.K.; Yuen K.Y.; Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011,52(4),447-456","journal-title":"Clin Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/jac\/dki346","volume":"56","author":"Yeh K.M.","year":"2005","unstructured":"Yeh K.M.; Chiueh T.S.; Siu L.K.; Lin J.C.; Chan P.K.S.; Peng M.Y.; Wan H.L.; Chen J.H.; Hu B.S.; Perng C.L.; Lu J.J.; Chang F.Y.; Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005,56(5),919-922","journal-title":"J Antimicrob Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Cheng Y.","year":"2005","unstructured":"Cheng Y.; Wong R.; Soo Y.O.Y.; Wong W.S.; Lee C.K.; Ng M.H.L.; Chan P.; Wong K.C.; Leung C.B.; Cheng G.; Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005,24(1),44-46","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","volume":"10","author":"Soo Y.O.Y.","year":"2004","unstructured":"Soo Y.O.Y.; Cheng Y.; Wong R.; Hui D.S.; Lee C.K.; Tsang K.K.S.; Ng M.H.L.; Chan P.; Cheng G.; Sung J.J.Y.; Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004,10(7),676-678","journal-title":"Clin Microbiol Infect"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3343\/alm.2016.36.4.393","volume":"36","author":"Chun S.","year":"2016","unstructured":"Chun S.; Chung C.R.; Ha Y.E.; Han T.H.; Ki C.S.; Kang E.S.; Park J.K.; Peck K.R.; Cho D.; Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with middle east respiratory syndrome. Ann Lab Med 2016,36(4),393-395","journal-title":"Ann Lab Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"Ko J.H.","year":"2018","unstructured":"Ko J.H.; Seok H.; Cho S.Y.; Ha Y.E.; Baek J.Y.; Kim S.H.; Kim Y.J.; Park J.K.; Chung C.R.; Kang E.S.; Cho D.; M&#xFC;ller M.A.; Drosten C.; Kang C.I.; Chung D.R.; Song J.H.; Peck K.R.; Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience. Antivir Ther 2018,23(7),617-622","journal-title":"Antivir Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.36468\/pharmaceutical-sciences.spl.438","volume":"84","author":"Yunus K.T.M.","year":"2022","unstructured":"Yunus K.T.M.; Badruddin I.A.; Saquib S.A.; Mohamed R.; Arora S.; Mohammed M.A.K.; Shamsuddin S.V.; Khateeb S.; Khan A.A.; Grover V.; Convalescent plasma therapy: A treatment of choice for COVID-19 during current pandemic. Indian J Pharm Sci 2022,84(1),235-245","journal-title":"Indian J Pharm Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ajem.2020.05.101","volume":"41","author":"Kumar S.","year":"2021","unstructured":"Kumar S.; Sharma V.; Priya K.; Battle against COVID-19: Efficacy of convalescent plasma as an emergency therapy. Am J Emerg Med 2021,41,244-246","journal-title":"Am J Emerg Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/jmv.25961","volume":"92","author":"Rajendran K.","year":"2020","unstructured":"Rajendran K.; Krishnasamy N.; Rangarajan J.; Rathinam J.; Natarajan M.; Ramachandran A.; Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020,92(9),1475-1483","journal-title":"J Med Virol"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9535","volume":"12","author":"Bakhtawar N.","year":"2020","unstructured":"Bakhtawar N.; Usman M.; Khan MMU.; Convalescent plasma therapy and its effects on COVID-19 patient outcomes: A systematic review of current literature. Cureus 2020,12(8)","journal-title":"Cureus"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"Li L.","year":"2020","unstructured":"Li L.; Zhang W.; Hu Y.; Tong X.; Zheng S.; Yang J.; Kong Y.; Ren L.; Wei Q.; Mei H.; Hu C.; Tao C.; Yang R.; Wang J.; Yu Y.; Guo Y.; Wu X.; Xu Z.; Zeng L.; Xiong N.; Chen L.; Wang J.; Man N.; Liu Y.; Xu H.; Deng E.; Zhang X.; Li C.; Wang C.; Su S.; Zhang L.; Wang J.; Wu Y.; Liu Z.; Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. JAMA 2020,324(5),460-470","journal-title":"JAMA"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4103\/0970-258X.296202","volume":"33","author":"Sharma A.","year":"2020","unstructured":"Sharma A.; Seth T.; Elavarasi A.; Sahoo R.K.; Shalimar; Madan, K.; Nischal, N.; Soneja, M.; Garg, P.; Prasad, K. Convalescent plasma therapy for COVID-19: A systematic review. Natl Med J India 2020,33(4),213-221","journal-title":"Natl Med J India"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/jca.21881","volume":"36","author":"Vegivinti C.T.R.","year":"2021","unstructured":"Vegivinti C.T.R.; Pederson J.M.; Saravu K.; Gupta N.; Evanson K.W.; Kamrowski S.; Schmidt M.; Barrett A.; Trent H.; Dibas M.; Reierson N.L.; Mikoff N.; Pisipati S.; Joseph B.A.; Selvan P.T.; Dmytriw A.A.; Pulakurthi Y.S.; Keesari P.R.; Sriram V.; Chittajallu S.; Brinjikji W.; Katamreddy R.R.; Chibbar R.; Davis A.R.; Malpe M.; Mishra H.K.; Kallmes K.M.; Hassan A.E.; Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis. J Clin Apher 2021,36(3),470-482","journal-title":"J Clin Apher"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.4103\/jfmpc.jfmpc_2429_20","volume":"10","author":"Ayub A.","year":"2021","unstructured":"Ayub A.; Agarwal N.; Mishra S.; Convalescent plasma therapy in COVID-19 and discharge status: A systematic review. J Family Med Prim Care 2021,10(10),3876-3881","journal-title":"J Family Med Prim Care"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/bjh.17270","volume":"192","author":"Casadevall A.","year":"2021","unstructured":"Casadevall A.; Tobian A.A.R.; Convalescent plasma for COVID-19 - encouraging signals of efficacy. Br J Haematol 2021,192(4),681-682","journal-title":"Br J Haematol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.clinpr.2021.100096","volume":"12","author":"Casarola G.","year":"2021","unstructured":"Casarola G.; D\u2019Abbondanza M.; Curcio R.; Alcidi R.; Campanella T.; Rossi R.; Fusaro J.; Gandolfo V.; Di Giuli C.; Laoreti C.; Veca V.; Leone M.C.; Pucci G.; Vaudo G.; Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report. Clin Infect Pract 2021,12,100096","journal-title":"Clin Infect Pract"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3906\/sag-2007-59","volume":"51","author":"Hacibekiro&#x11F;lu T.","year":"2021","unstructured":"Hacibekiro&#x11F;lu T.; Kalpak&#xE7;\u0131 Y.; Gen&#xE7;, AC Efficacy of convalescent plasma according to blood groups in COVID-19 patients. Turk J Med Sci 2021,51(1),45-48","journal-title":"Turk J Med Sci"},{"key":"ref=53","first-page":"152","volume":"14","author":"Marano G.","year":"2016","unstructured":"Marano G.; Vaglio S.; Pupella S.; Facco G.; Catalano L.; Liumbruno G.M.; Grazzini G.; Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus 2016,14(2),152-157","journal-title":"Blood Transfus"},{"key":"ref=54","author":"Xinhua T.S.C.I.O.","year":"2020","unstructured":"Xinhua T.S.C.I.O.;  Fighting COVID-19: China in action 2020","journal-title":"Fighting COVID-19: China in action"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"Peiris J.S.M.","year":"2003","unstructured":"Peiris J.S.M.; Chu C.M.; Cheng V.C.C.; Chan K.S.; Hung I.F.N.; Poon L.L.M.; Law K.I.; Tang B.S.F.; Hon T.Y.W.; Chan C.S.; Chan K.H.; Ng J.S.C.; Zheng B.J.; Ng W.L.; Lai R.W.M.; Guan Y.; Yuen K.Y.; Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003,361(9371),1767-1772","journal-title":"Lancet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM200307313490520","volume":"349","author":"Li G.","year":"2003","unstructured":"Li G.; Chen X.; Xu A.; Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 2003,349(5),508-509","journal-title":"N Engl J Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"Luke T.C.","year":"2006","unstructured":"Luke T.C.; Kilbane E.M.; Jackson J.L.; Hoffman S.L.; Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006,145(8),599-609","journal-title":"Ann Intern Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.beha.2005.01.033","volume":"19","author":"MacLennan S.","year":"2006","unstructured":"MacLennan S.; Barbara J.A.J.; Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006,19(1),169-189","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref=59","first-page":"1018","volume":"83","author":"Zhou X.Z.","year":"2003","unstructured":"Zhou X.Z.; Zhao M.; Wang F.S.; Jiang T.J.; Li Y.G.; Nie W.M.; Zhou Z.P.; Wang Y.; He J.; Fan R.; Zhao J.M.; Zhang X.W.; Epidemiologic features, clinical diagnosis and therapy of first cluster of patients with severe acute respiratory syndrome in Beijing area. Zhonghua Yi Xue Za Zhi 2003,83(12),1018-1022","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1213\/ane.0b013e3181930a6e","volume":"108","author":"Hendrickson J.E.","year":"2009","unstructured":"Hendrickson J.E.; Hillyer C.D.; Noninfectious serious hazards of transfusion. Anesth Analg 2009,108(3),759-769","journal-title":"Anesth Analg"},{"key":"ref=61","first-page":"1","year":"2014","unstructured":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during. 2014,1-19"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35248\/2167-0870.20.10.409","volume":"10","author":"Anudeep T.C.","year":"2020","unstructured":"Anudeep T.C.; Jeyaraman M.; Shetty D.U.; Raj H.; Ss A.; Somasundaram R.; Kumar V.; Jain R.; Dilip S.; Convalescent plasma as a plausible therapeutic option for nCOVID-19: A review. J Clin Trials 2020,10,1-7","journal-title":"J Clin Trials"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tmrv.2020.04.001","volume":"34","author":"Sullivan H.C.","year":"2020","unstructured":"Sullivan H.C.; Roback J.D.; Convalescent plasma: Therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev 2020,34(3),145-150","journal-title":"Transfus Med Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1084\/jem.113.5.935","volume":"113","author":"Uhr J.W.","year":"1961","unstructured":"Uhr J.W.; Baumann J.B.; Antibody formation I. The suppression of antibody formation by passively administered antibody. J Exp Med 1961,113(5),935-957","journal-title":"J Exp Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"Duan K.","year":"2020","unstructured":"Duan K.; Liu B.; Li C.; Zhang H.; Yu T.; Qu J.; Zhou M.; Chen L.; Meng S.; Hu Y.; Peng C.; Yuan M.; Huang J.; Wang Z.; Yu J.; Gao X.; Wang D.; Yu X.; Li L.; Zhang J.; Wu X.; Li B.; Xu Y.; Chen W.; Peng Y.; Hu Y.; Lin L.; Liu X.; Huang S.; Zhou Z.; Zhang L.; Wang Y.; Zhang Z.; Deng K.; Xia Z.; Gong Q.; Zhang W.; Zheng X.; Liu Y.; Yang H.; Zhou D.; Yu D.; Hou J.; Shi Z.; Chen S.; Chen Z.; Zhang X.; Yang X.; Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci 2020,117(17),9490-9496","journal-title":"Proc Natl Acad Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2020.03.30.20047365","DOI":"10.2139\/ssrn.3566211","author":"Wu F.","year":"2020","unstructured":"Wu F.; Wang A.; Liu M.; Wang Q.; Chen J.; Xia S.; Ling Y.; Zhang Y.; Xun J.; Lu L.; Neutralizing antibody responses to sars-cov-2 in a COVID-19 recovered patient cohort and their implications. SSRN 2020,2020.03.30.20047365","journal-title":"SSRN"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"Shen C.","unstructured":"Shen C.; Wang Z.; Zhao F.; Yang Y.; Li J.; Yuan J.; Wang F.; Li D.; Yang M.; Xing L.; Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA2020 ,323,1582-1589","journal-title":"JAMA2020"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","volume":"158","author":"Zhang B.","year":"2020","unstructured":"Zhang B.; Liu S.; Tan T.; Huang W.; Dong Y.; Chen L.; Chen Q.; Zhang L.; Zhong Q.; Zhang X.; Zou Y.; Zhang S.; Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020,158(1),e9-e13","journal-title":"Chest"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.25882","volume":"92","author":"Ye M.","year":"2020","unstructured":"Ye M.; Fu D.; Ren Y.; Wang F.; Wang D.; Zhang F.; Xia X.; Lv T.; Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol 2020,92(10),1890-1901","journal-title":"J Med Virol"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"Ahn J.Y.","year":"2020","unstructured":"Ahn J.Y.; Sohn Y.; Lee S.H.; Cho Y.; Hyun J.H.; Baek Y.J.; Jeong S.J.; Kim J.H.; Ku N.S.; Yeom J.S.; Roh J.; Ahn M.Y.; Chin B.S.; Kim Y.S.; Lee H.; Yong D.; Kim H.O.; Kim S.; Choi J.Y.; Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020,35(14)","journal-title":"J Korean Med Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.2020.4940","volume":"323","author":"Roback J.D.","year":"2020","unstructured":"Roback J.D.; Guarner J.; Convalescent plasma to treat COVID-19. JAMA 2020,323(16),1561-1562","journal-title":"JAMA"},{"key":"ref=72","author":"Denise M.","year":"2020","unstructured":"Denise M.; Emergency use authorization for COVID-19 convalescent plasma. U.S. Food and Drug Admin., U.S. Dep\u2019t of Health and Human Servs. Available from: 2020"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2021.12.10.21267485","DOI":"10.1101\/2021.12.10.21267485","author":"Sullivan D.J.","unstructured":"Sullivan D.J.; Gebo K.A.; Shoham S.; Randomized controlled trial of early outpatient COVID-19 treatment with high-titer convalescent plasma. medRxiv ,2021.12.10.21267485","journal-title":"medRxiv"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"21268317","DOI":"10.1101\/2021.12.24.21268317","volume":"12","author":"Focosi D.","year":"2021","unstructured":"Focosi D.; Massimo F.; Michael J.J.; Arturo C.; Comparative analysis of antibody responses from COVID-19 convalescents receiving various vaccines reveals consistent high neutralizing activity for SARS-CoV-2 variant of concern. OMICRO Nmed Rxiv 2021,12(24),21268317","journal-title":"OMICRO Nmed Rxiv"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230202144314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213392\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230202144314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T15:06:23Z","timestamp":1691334383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213392\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666230202144314","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}